Primary Myelofibrosis clinical trials

Explore recruiting primary myelofibrosis clinical trials.

Recruiting primary myelofibrosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Primary Myelofibrosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Open-Label Study to Evaluate Momelotinib in combination with Luspatercept in Participants with Transfusion Dependent Primary or Secondary Myelofibrosis

France, Italy, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)

Italy, Bulgaria, Denmark, Spain, Poland, Belgium +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

PACIFICA Phase 3: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL)

Hungary, Czechia, Romania, Spain, Italy, Bulgaria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS - intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib

Belgium, Italy, Hungary, France, Czechia, Germany +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV MF), Or Post Essential Thrombocythemia MF (Post ET MF) Who Have a Suboptimal Response to Ruxolitinib

France, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

HOVON 172 MF: A phase 1b/2 trial with tasquinimod in patients with myelofibrosis (primary, post-PV or post-ET) refractory to or intolerant for JAK2 inhibition: the TasqForce trial

Germany, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Primary Myelofibrosis trials by city

Primary Myelofibrosis in Toronto Primary Myelofibrosis in Vancouver Primary Myelofibrosis in Montreal Primary Myelofibrosis in Calgary Primary Myelofibrosis in Edmonton Primary Myelofibrosis in Ottawa Primary Myelofibrosis in Winnipeg Primary Myelofibrosis in Quebec City Primary Myelofibrosis in Hamilton Primary Myelofibrosis in Kitchener Primary Myelofibrosis in London Primary Myelofibrosis in Halifax Primary Myelofibrosis in New York Primary Myelofibrosis in Los Angeles Primary Myelofibrosis in Chicago Primary Myelofibrosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease